Table of Contents
Biopharma Is on the Most Aggressive Buying Spree in Years
The first quarter of 2026 has produced nearly $47 billion in biopharma mergers and acquisitions, with deal-hungry pharmaceutical giants paying premium prices for companies that have already cleared the hardest hurdle in the industry: clinical proof. Biogen, Eli Lilly, Merck, and Novartis collectively spent more than $20 billion acquiring biotechs with promising or fully approved drugs. The rare disease space notched multiple fresh approvals from the FDA. And a new wave of biotech IPOs is gathering momentum, with AI cited as one of the primary forces behind investor confidence returning to the sector.
This is not a speculative bubble. These are transactions built on clinical data, commercial revenue, and pipelines that address conditions with few or no existing treatments. The pace of activity reflects how much ground the industry believes it needs to cover before patent cliffs hit established blockbuster drugs and before rival companies lock up the same assets.
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
Biogen announced the acquisition of Apellis Pharmaceuticals for $5.6 billion this week, securing two approved drugs: Syfovre and Empaveli. Syfovre targets geographic atrophy, a form of advanced age-related macular degeneration that affects millions of patients globally and has historically had no approved treatment option. Empaveli is approved for paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
The deal also brings strategic depth to Biogen’s kidney disease portfolio. Biogen is preparing to launch felzartamab, its own nephrology asset currently in multiple Phase 3 trials. Acquiring Apellis adds a commercial nephrology team with established payer relationships and clinical credibility in the field, which shortens the go-to-market timeline for felzartamab significantly.
The transaction uses a contingent value right, a structure that pays Apellis shareholders additional amounts if future commercial milestones are achieved. CVRs have seen renewed use in 2026 as a mechanism for bridging valuation disagreements between acquirer and target in a market where clinical outcomes are uncertain but the strategic rationale is strong.
Eli Lilly Buys Centessa Pharmaceuticals for $6.3 Billion
Eli Lilly announced its $6.3 billion acquisition of Centessa Pharmaceuticals this week to strengthen its neuroscience pipeline. Centessa brings two clinical-stage drugs targeting the OX2 receptor, a mechanism relevant to sleep disorders including narcolepsy. The acquisition fills a gap in Lilly’s portfolio and intensifies competition with established sleep disorder players Takeda and Eisai.
Lilly’s M&A activity in 2026 is strategically consistent: the company is using the extraordinary commercial success of its GLP-1 drugs, Mounjaro and Zepbound, to fund acquisitions in therapeutic categories where it has historically been underrepresented. Neuroscience, kidney disease, and oncology are the three areas receiving the most capital allocation. Centessa fits squarely in the neuroscience column.
Biotech IPOs Are Back, and AI Is Why
After a difficult 2025 that saw an extended drought in biotech public offerings, the IPO window has reopened in 2026. Kailera Therapeutics, an obesity-focused company that raised $1 billion in venture funding since its launch in 2024, filed plans for an IPO this week. The company is developing a GLP-1 competitor that is now in late-stage testing, positioning it directly in the most commercially significant pharmaceutical category in the world.
BioSpace’s analysis of the IPO rebound points to AI as a key factor. The combination of AI-assisted drug discovery, which compresses the time from target identification to clinical candidate by 30 to 50% in some pipelines, and AI-powered clinical trial design, which improves patient stratification and endpoint selection, has made biotech fundamentals more credible to institutional investors who burned themselves on pre-clinical-stage companies during the 2021 boom.
OrbiMed and RA Capital are among the most active investors this quarter, having backed oral peptide drugmaker Pinnacle Medicines and several other early-stage companies working at the intersection of AI and biology.
The Cancer Treatment Breakthrough Worth Watching
Researchers published findings this week showing that inhibiting LSD1 and PARP1 simultaneously in BAP1-deficient tumors disrupts DNA repair, leading to tumor shrinkage and improved survival in mouse models across several cancer types. The combination includes drugs like Lynparza that are already approved for other indications. The researchers note that further clinical studies are needed before the combination can be confirmed as safe and effective in humans, but the mechanism is compelling because it targets a broad class of tumors defined by a genetic defect rather than a specific organ of origin.
This research direction, identifying cancer vulnerabilities that transcend tissue type and designing treatments around those vulnerabilities, is one of the areas where AI is having the most measurable impact. AI tools that analyze large genomic datasets can identify these cross-tumor patterns faster than traditional wet lab discovery approaches, which is why AI-native drug discovery companies are attracting serious institutional capital in 2026.
Wearables Are Coming for Pharma and Biotech
The wearables market specifically serving pharmaceutical and biotech applications is projected to grow from approximately $4 billion in 2026 to nearly $10 billion within five years. The use case is distinct from consumer wellness wearables: these devices are used in clinical trials to continuously monitor patient biomarkers, detect adverse events in real time, and generate the kind of longitudinal data that traditionally required expensive hospital visits or in-clinic monitoring.
For drug developers, continuous remote monitoring via wearables means faster signal detection, lower trial dropout rates because of reduced patient burden, and richer datasets that support more refined regulatory submissions. The FDA has been receptive to wearable-generated endpoints in recent guidance updates, which removes one of the key barriers to commercial adoption.
AI Drug Discovery: From Hype to Commercial Reality
Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, dosed its first patient in a Phase 1 clinical trial this week. The company used AI to identify a novel target, design the drug candidate, and optimize its structure, completing a process in 18 months that would conventionally take five to seven years.
AvenCell Therapeutics advanced its switchable CAR-T cell therapy program this week, adding data from the most recent dosing cohort to its growing clinical dataset. CAR-T therapies are among the most technically complex products in the pharmaceutical industry, requiring individualized manufacturing and precise administration. AI is being applied to optimize every step of the manufacturing process, from cell selection through quality release testing.
Caris Life Sciences, a precision medicine pioneer that recently listed on Nasdaq, is positioning itself at the intersection of AI and molecular diagnostics. The company’s platform generates comprehensive molecular profiles of tumor samples and uses AI to match patients to treatments, including clinical trials, with a degree of precision that traditional pathology cannot match.
What to Watch in Q2 2026
The FDA has several high-profile decisions queued for Q2, including a review of a new obesity drug that could intensify an already fierce competitive landscape between Lilly, Novo Nordisk, and a growing number of challengers. Revolution Medicines and Ascendis Pharma, identified as prime buyout targets by analysts, remain at the center of acquisition speculation. The rare disease space continues to generate both clinical successes and cautionary tales: the FDA’s decision to ask Amgen to pull Tavneos from the market over liver toxicity concerns is a reminder that even approved drugs face ongoing post-market scrutiny.
Biotech in 2026 is not a sector for the faint of heart or the short of patience. But the combination of AI-accelerated discovery, a more receptive regulatory environment, commercial validation of novel mechanisms in obesity and immunology, and a reopened IPO market makes this one of the most interesting periods in the industry’s history.
